Replies to post #35504 on Cel Sci Corporation (CVM)

[GD]

The best case is BP buyout for NWBO so the buyer can try
combo trials, if the subgroup has very strong and clean OS
data, FDA's approval is all depend on Richard Pazdur's view,
my experiences is no approval because BP does not want NWBO
to succeed, we better hope MK trial has a clean strong efficacy
so the approval does not rely on any one's view in FDA.
Here is what I see how NWBO play out, buyout price 3 to 3.5B,
2.5-3/share on full diluted 1.2B shares, no buyout, muddy
results, stay here $1.5 if street see a fighting chance
of approval, a $250M to $300M secondary offering. Any way
I see NWBO, the upside is limited.

[RobotDroid]

They did change the end points probably to their advantage. I believe NWBO will have positive results, just like CVM.